Skip to main content
Aprea Therapeutics, Inc. logo

Aprea Therapeutics, Inc. — Investor Relations & Filings

Ticker · APRE ISIN · US03836J1025 US Professional, scientific and technical activities
Open in API
Filings indexed 405 across all filing types
Latest filing 2023-02-10 Investor Presentation
Country US United States of America
Listing US APRE

About Aprea Therapeutics, Inc.

https://www.aprea.com/

Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops and commercializes novel cancer therapeutics. The company focuses on precision oncology through a synthetic lethality-based approach, targeting DNA Damage Response (DDR) pathways. Its pipeline consists of small molecule therapeutics designed to exploit vulnerabilities associated with cancer cell mutations, aiming to maximize clinical activity and selectivity while minimizing toxicity. Aprea Therapeutics is conducting clinical trials to evaluate its programs in patients with advanced solid tumors.

Recent filings

Filing Released Lang Actions
FORM 8-K
Investor Presentation Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated February 10, 2023, by Aprea Therapeutics, Inc. The key content is an update to the company's corporate presentation intended for investor meetings, which is attached as Exhibit 99.1. The document does not contain financial statements or detailed financial analysis but rather announces the filing of a presentation. The length is 3476 characters, which is relatively short and consistent with an announcement rather than a full report. According to the classification rules, this type of document is best classified as an Investor Presentation (IP).
2023-02-10 English
OWNERSHIP DOCUMENT
Director's Dealing
2023-01-30 English
OWNERSHIP DOCUMENT
Director's Dealing
2023-01-30 English
FORM 8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated January 30, 2023, which is a current report used to announce major events that shareholders should know about. The content specifically details the departure of a Chief Financial Officer and the appointment of a new CFO, including employment terms and separation agreements. This matches the description of announcements related to changes in the company's board of directors or senior management. There are no financial statements or detailed financial data presented, so it is not an Annual Report, Interim Report, or Earnings Release. The document is not a proxy statement, voting results, or a regulatory filing of another type. Therefore, the appropriate classification is Board/Management Information (MANG). The document length is over 11,000 characters, indicating it is a full report rather than a brief announcement or certification. Confidence in this classification is high due to the clear focus on management changes and the nature of Form 8-K filings for such events.
2023-01-30 English
FORM 8-K
Investor Presentation Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated January 26, 2023. It announces that Aprea Therapeutics will be presenting at the 6th Annual DDR Inhibitors Summit and includes presentation slide decks as exhibits. The document is relatively short (3629 characters) and primarily serves to announce the presentation and provide the slides, not a full financial report or detailed analysis. This fits the profile of an Investor Presentation (IP) filing rather than a full Annual Report, Earnings Release, or other report types. Therefore, the classification is Investor Presentation (IP).
2023-01-26 English
FORM 8-K
Investor Presentation Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated January 9, 2023, by Aprea Therapeutics, Inc. The key content is an update to the company's corporate presentation intended for investor meetings, which is attached as Exhibit 99.1. The document does not contain financial statements or detailed financial analysis but rather announces the filing of a presentation. The length is 3546 characters, which is relatively short and consistent with an announcement rather than a full report. According to the classification rules, such a document that announces or attaches a presentation for investors is best classified as an Investor Presentation (IP).
2023-01-09 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.